MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted U.S. patent 12,102,611, Compositions And Methods For Treating Hypertension By Modulating Endocrine Activity, for its breakthrough food ingredient formulation that reduces high blood pressure. Protenx™ Blood Pressure can reduce blood pressure without the side effects and drawbacks of current pharmaceutical solutions, using food molecules from the FDA-approved GRAS (Generally Recognized As Safe) list.
The Protenx™ formulation will be available as a supplement sold direct to consumers in Q2 of next year. Also, food & beverage companies will add Protenx Blood Pressure to their consumer products, bringing the potential of achieving various benefits consistent with current prescription-only pharmaceuticals, without side effects and without requiring any changes in consumer behavior or routines.
“We are excited to have been granted this patent for Protenx Blood Pressure, the second formulation in our line of Protenx products. The markets for reducing blood pressure and for hypertensive endocrine diseases and disorders are very large, and our new product will help consumers tackle these conditions inexpensively and easily, with no side effects,” said Nils Lommerin, President and CEO of Olfactive Biosolutions.
Hypertension is one of the most widespread chronic diseases in the U.S. and is estimated by the Centers for Disease Control and Prevention (CDC) to cost the United States more than $131 billion a year in healthcare costs. The CDC also estimates that at least 47 percent of U.S. adults (approximately 121.5 million people) have high blood pressure, which significantly increases the risk of developing numerous life-threatening diseases and disorders.
Although pharmaceuticals and therapies prescribed for high blood pressure have generally been effective in treating essential hypertension, there are several disadvantages associated with them, including adverse reactions when prescribed with other medications. Additionally, some subjects have hypertension that is broadly resistant to pharmaceuticals, commonly referred to as resistant hypertension. Resistant hypertension often requires more aggressive treatment measures and can be very difficult to treat with pharmaceutically active agents alone. Protenx Blood Pressure offers an effective alternative for these patients.
“An alternative and widely applicable treatment for hypertension has been long sought after,” said cardiovascular surgeon Robert Matheny, MD, Chief Scientific and Medical Officer for Cormatrix Cardiovascular. “Protenx Blood Pressure may very well provide the answer, while at the same time offering relief from often encountered side-effects. This novel approach will open the door for treating a vast and growing number of patients and in such a way I believe will be accompanied by much greater compliance.”
The Olfactive Biosolutions team has deep expertise in receptor protein science and the food & beverage industry. The company has several well-known biotechnology advisors from academia and the corporate world; its President and CEO is a former President, CEO and Director of Del Monte Foods.
About Olfactive Biosolutions
Olfactive Biosolutions is the leader in adapting food molecules to treat chronic diseases. It has developed world-leading receptor technology and expertise in both ectopic receptors in the gut, lungs, skin, heart, blood and elsewhere, and olfactory and taste receptors in the nose and tongue.
Its unique technology demonstrates how ectopic receptors often perform the same physiological tasks as active pharmaceutical ingredients or APIs, and what ligands activate or inhibit them.
To learn more, visit https://olfactive.bio or follow us on LinkedIn.